Ownership of Sponsor Drug and Comparator Drug Sample Clauses

Ownership of Sponsor Drug and Comparator Drug. Vlastnictví léku zadavatele a srovnávacího léku. Sponsor Drug and Comparator Drug are and shall remain at all times the property of Sponsor. Sponsor grants Health Service Provider no express or implied intellectual property rights in the Sponsor Drug or and Comparator Drug, or in any methods of making or using the Sponsor Drug or Comparator Drug. Lék zadavatele a srovnávací lék jsou a trvale zůstanou ve vlastnictví zadavatele. Zadavatel neuděluje poskytovateli zdravotních služeb žádná výslovná ani implicitní práva k léku zadavatele a/nebo srovnávacího léku ani jakýmkoli způsobům jejich výroby nebo používání.
AutoNDA by SimpleDocs
Ownership of Sponsor Drug and Comparator Drug. V lastnictví léku zadavatele a srovnávacího léku. Sponsor Drug and Comparator Drug are and shall remain at all times the property of Sponsor. Sponsor grants Institution no express or implied intellectual property rights in the Sponsor Drug or and Comparator Drug, or in any methods of making or using the Sponsor Drug or Comparator Drug. Lék zadavatele a srovnávací lék jsou a trvale zůstanou ve vlastnictví zadavatele. Zadavatel neuděluje zdravotnickému zařízení žádná výslovná ani implicitní práva k léku zadavatele a/nebo srovnávacího léku ani jakýmkoli způsobům jejich výroby nebo používání. The Sponsor at their own expense will arrange for the disposal of the unused medications Likvidaci nevyužitých léků zadavatel zajistí na vlastní náklady. Sponsor undertakes that, as a waste producer, it will at its own expense ensure that unused Study Drug is handed to the authorized person according to Act No. 185/2001 Coll., on Waste, as amended. Zadavatel se jako původce odpadu zavazuje, že zajistí na vlastní náklady, jak v průběhu, tak i po skončení klinického hodnocení, předání nepoužitelného a nepoužitého léčivého přípravku oprávněné osobě v souladu s ustanoveními zákona č. 185/2001 Sb., o odpadech a jeho prováděcími předpisy v platném znění. Sponsor represents to meet any and all conditions stipulated by the relevant legislation concerning the manufacture (import) of the Sponsor Drug and their distribution to the Institution. Zadavatel prohlašuje, že jsou splněny veškeré podmínky stanovené příslušnými právními předpisy pro výrobu (dovoz) léku zadavatele a jeho distribuci do zdravotnického zařízení. The Parties acknowledge and confirm that the Trial, which is subject to this Agreement, is entirely independent from any persuasion to purchase medicinal products (medical devices) from CRO or the Sponsor, or from any decisions to purchase medicinal products (medical devices’) from CRO or the Sponsor, and shall Smluvní strany shodně prohlašují, že klinické hodnocení dle této smlouvy nijak nesouvisí s odběrem léčivých přípravků (zdravotnických prostředků) od CRO nebo zadavatele, jakož i případným rozhodováním o pořízení léčivých prostředků (zdravotnických prostředků) od CRO nebo zadavatele, ani neovlivní existující nebo have no impact on any ongoing or future agreements that may exist between CRO, the Sponsor, and the Institution. budoucí smluvní vztahy mezi CRO, zadavatelem a zdravotnickým zařízením.
Ownership of Sponsor Drug and Comparator Drug. Vlastnictví léku zadavatele a srovnávacího léku. Sponsor Drug and Comparator Drug are and shall remain at all times the property of Sponsor. Sponsor grants Institution no express or implied intellectual property rights in the Sponsor Drug or and Comparator Drug, or in any methods of making or using the Sponsor Drug or Comparator Drug. Lék zadavatele a srovnávací lék jsou a trvale zůstanou ve vlastnictví zadavatele. Zadavatel neuděluje zdravotnickému zařízení žádná výslovná ani implicitní práva k léku zadavatele a/nebo srovnávacího léku ani jakýmkoli způsobům jejich výroby nebo používání. The Sponsor at their own expense will arrange for the disposal of the unused medications Likvidaci nevyužitých léků zadavatel zajistí na vlastní náklady. At their own expense, during the clinical Trail and upon its completion, sponsor undertakes to, as the source of waste, hand over any unusable Sponsor´s Drug and Comparator Drug to an authorised person in accordance with Act No.185/2001 Coll. on Waste and its implementing regulations, as amended. Zadavatel se jako původce odpadu zavazuje, že zajistí na vlastní náklady, jak v průběhu, tak i po skončení klinického hodnocení, předání nepoužitelného léku zadavatele a srovnávacího léku oprávněné osobě v souladu s ustanoveními zákona č. 185/2001 Sb., o odpadech a jeho prováděcími předpisy v platném znění. Sponsor represents to meet any and all conditions stipulated by the relevant legislation concerning the manufacture (import) of the Investigational Products and their distribution to Zadavatel prohlašuje, že jsou splněny veškeré podmínky stanovené příslušnými právními předpisy pro výrobu (dovoz) léku zadavatele a jeho distribuci do zdravotnického zařízení. the Institution. The Parties acknowledge and confirm that the Trial, which is subject to this Agreement, is entirely independent from any persuasion to purchase medicinal products (medical devices) from CRO or the Sponsor, or from any decisions to purchase medicinal products (medical devices’) from CRO or the Sponsor, and shall have no impact on any ongoing or future agreements that may exist between ICON, the Sponsor, and the Institution. Smluvní strany shodně prohlašují, že klinické hodnocení dle této smlouvy nijak nesouvisí s odběrem léčivých přípravků (zdravotnických prostředků) od CRO nebo zadavatele, jakož i případným rozhodováním o pořízení léčivých prostředků (zdravotnických prostředků) od CRO nebo zadavatele, ani neovlivní existující nebo budoucí smluvní vztahy mezi...

Related to Ownership of Sponsor Drug and Comparator Drug

  • Function of Joint Health and Safety Committee All incidents involving aggression or violence shall be brought to the attention of the Joint Health and Safety Committee. The Employer agrees that the Joint Health and Safety Committee shall concern itself with all matters relating to violence to staff.

  • COVID-19 Protocols Contractor will abide by all applicable COVID-19 protocols set forth in the District’s Reopening and COVID-19 Mitigation Plan and the safety guidelines for COVID-19 prevention established by the California Department of Public Health and the Ventura County Department of Public Health.

  • REGULATORY FILINGS AND CAISO TARIFF COMPLIANCE 3.1 Filing

  • Drug and Alcohol Testing – Safety-Sensitive Functions A. Employees required to have a Commercial Driver’s License (CDL) are subject to pre-employment, post-accident, random and reasonable suspicion testing in accordance with the U.S. Department of Transportation rules, Coast Guard Regulations (46 CFR Part 16) or the Federal Omnibus Transportation Employee Testing Act of 1991. The testing will be conducted in accordance with current Employer policy.

  • Information Technology Enterprise Architecture Requirements If this Contract involves information technology-related products or services, the Contractor agrees that all such products or services are compatible with any of the technology standards found at xxxxx://xxx.xx.xxx/iot/2394.htm that are applicable, including the assistive technology standard. The State may terminate this Contract for default if the terms of this paragraph are breached.

  • Prescription Drug Plan Effective July 1, 2011, retail and mail order prescription drug copays for bargaining unit employees shall be as follows: Type of Drug Prescriptions for 1-45 Days (1 copay) Prescriptions for 46-90 Days (2 copays) Generic drug $10 $20 Preferred brand name drug $25 $50 Non-preferred brand name drug $40 $80 Effective July 1, 2011, for each plan year the Prescription Drug annual out-of- pocket copay maximum shall be $1,000 for individual coverage and $1,500 for employee and spouse, employee and child, or employee and family coverage.

  • Prescription Drug Quantity Limits We limit the quantity of certain prescription drugs that you can get at one time for safety, cost-effectiveness and medical appropriateness reasons. Our clinical criteria for quantity limits are subject to our periodic review and modification. Quantity limits may restrict: • the amount of pills dispensed per thirty (30) day period; • the number of prescriptions ordered in a specified time period; or • the number of prescriptions ordered by a provider, or multiple providers. Our formulary indicates which prescription drugs have a quantity limit. Types of Pharmacies Prescription drugs and diabetic equipment or supplies can be bought from the following types of pharmacies: • Retail pharmacies. These dispense prescription drugs and diabetic equipment or supplies. • Mail order pharmacies. These dispense maintenance and non-maintenance prescription drugs and diabetic equipment or supplies. • Specialty pharmacies. These dispense specialty prescription drugs, defined as such on our formulary. For information about our network retail, mail order, and specialty pharmacies, visit our website or call our Customer Service Department.

  • Reactive Power and Primary Frequency Response 9.6.1 Power Factor Design Criteria

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Drug and Alcohol Testing Permitted Testing is permitted where the Employer has reasonable suspicion to believe.

Time is Money Join Law Insider Premium to draft better contracts faster.